ClinicalTrials.gg

Program

miricorilant

Also written as “Miricorilant”, “Miricorlilant” and “Miricorilant (Cohort A)”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Weight Gain, led by Corcept Therapeutics.

Furthest: phase 2, since Jan 14, 201914 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Corcept Therapeutics140 open or runningphase 2since Jan 14, 2019Sep 27, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2017First study: phase 1 study in HealthyFirst studyNCT03315338 · 143 enrolled · United Kingdom
  2. Jan 14, 20192 phase 2 studiesNCT03823703, NCT03818256
  3. Mar 14, 20192 phase 1 studiesNCT03878264, NCT03877562
  4. Aug 6, 2020Phase 2 study in ObesityNCT04524403 · 150 enrolled · United States
  5. Dec 14, 2020Phase 1 study in HealthyNCT04672499 · 36 enrolled · United Kingdom
  6. Oct 12, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05117489 · 70 enrolled · United States
  7. Sep 21, 2022Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05553470 · 19 enrolled · United States
  8. Jan 25, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05712265 · 26 enrolled · United States
  9. Oct 23, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06108219 · 175 enrolled · United States, India, Puerto Rico
  10. Apr 21, 2025Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06947304 · 9 enrolled · United States
  11. Nov 7, 2025Phase 1 study in HealthyNCT07240116 · 18 enrolled · United States
  12. Apr 14, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07553663 · 14 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553663Non-alcoholic Fatty Liver Disease · United States1CompletedSep 22, 202614
NCT07240116Healthy · United States1CompletedMar 3, 202618
NCT06947304Non-alcoholic Fatty Liver Disease · United States1CompletedAug 13, 20269
NCT06108219Non-alcoholic Fatty Liver Disease · United States, India, Puerto Rico2CompletedFeb 13, 2026175
NCT05712265Non-alcoholic Fatty Liver Disease · United States1CompletedFeb 23, 202326
NCT05553470Non-alcoholic Fatty Liver Disease · United States1CompletedSep 13, 202419
NCT05117489Non-alcoholic Fatty Liver Disease · United States1CompletedJan 29, 202470
NCT04672499Healthy · United Kingdom1CompletedSep 7, 202036
NCT04524403Obesity · United States2CompletedJul 29, 2022150
NCT03878264Healthy · United Kingdom1CompletedMar 24, 201912
NCT03877562Antipsychotic-induced Weight Gain · United Kingdom1CompletedMar 13, 202096
NCT03818256Obesity · United States2CompletedJun 17, 202271
NCT03823703Non-alcoholic Fatty Liver Disease · United States2TerminatedApr 5, 202112
NCT03315338Healthy · United Kingdom1CompletedFeb 22, 2019143

How it is read

Names in the registry

  • “Miricorilant”, 6 entries
  • “Miricorlilant”, 2 entries
  • “Miricorilant (Cohort A)”, 1 entry
  • “Miricorilant (Cohort B)”, 1 entry
  • “Miricorilant Treatment A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.